Vesalio Expands Sales Network, Initiates Virtual Physician Training and

Announces High First Pass Effect Rate Publication

Vesalio Expands Sales Network, Initiates Virtual Physician Training and Announces High First
Pass Effect Rate Publication

Nashville, TN, September 16, 2020 --(PR.com)-- Vesalio announces it has executed additional exclusive
distribution agreements in Europe, Latin America, Asia and the Middle East. With these new
partnerships, the NeVa™ Thrombectomy System has gained market coverage in 53 countries. “The
expansion of the NeVa product line and impressive clinical data are driving strong interest from top
distribution companies globally, accelerating our growth momentum. We expect to add additional
markets by the end of 2020 and into 2021 as we approach US FDA clearance,” reported William von
Brendel, VP, International Business.

To support the onboarding of stroke centers in the expanded markets, Vesalio has broadened its training
programs to include NeVa Induction Webinars™. This virtual platform has allowed Vesalio to onboard
over 20 stroke centers in the past three months. Diane Demet Tangun, VP, Market Development
commented, “Enhancing virtual training was necessary given the limitations posed by the pandemic and
the desire of new physicians to utilize Vesalio’s Drop Zone™ technology. The NeVa first pass
recanalization rates attained by physicians continue to impress and drive new interest.”

A recent NeVa publication by Akpinar et al. in Interventional Neuroradiology once again reports
remarkable first-pass recanalization rates in a multi-center, real-life setting. “The data from this study is
particularly compelling as the high rate of first pass success was achieved largely without the use of
balloon guide catheters, which demonstrates the effectiveness and versatility of the NeVa platform,”
remarked Tangun.

About Vesalio, LLC

Founded in 2013, Vesalio is a privately held medical device company focused on advancing patient care
in vascular occlusion by providing physicians superior technology designed to improve clinical outcomes.
The Company’s proprietary NeVa™ platform was designed to consistently achieve first-pass
recanalization in acute ischemic stroke by effectively removing all types of neuro-vascular clots from
patient anatomy.

For further information, visit www.vesalio.com or email info@vesalio.com. NeVa trademarks and patents
are the property of Vesalio.

Page 1/2
PR.com Press Release Distribution Terms of Use
Contact Information:
Vesalio
William von Brendel
858-335-5790
Contact via Email
www.vesalio.com

Online Version of Press Release:

You can read the online version of this press release at: https://www.pr.com/press-release/821437

News Image:

Page 2/2
PR.com Press Release Distribution Terms of Use